Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Assets (2020 - 2025)

Historic Assets for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $370.2 million.

  • Xeris Biopharma Holdings' Assets rose 1528.69% to $370.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $370.2 million, marking a year-over-year increase of 1528.69%. This contributed to the annual value of $323.1 million for FY2024, which is 14.2% up from last year.
  • Xeris Biopharma Holdings' Assets amounted to $370.2 million in Q3 2025, which was up 1528.69% from $334.7 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Assets' 5-year high stood at $370.2 million during Q3 2025, with a 5-year trough of $131.3 million in Q3 2021.
  • Over the past 5 years, Xeris Biopharma Holdings' median Assets value was $323.1 million (recorded in 2024), while the average stood at $316.0 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Assets soared by 13085.25% in 2022, and later plummeted by 636.24% in 2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Assets (Quarter) stood at $304.4 million in 2021, then grew by 13.2% to $344.5 million in 2022, then decreased by 6.36% to $322.6 million in 2023, then rose by 0.14% to $323.1 million in 2024, then increased by 14.59% to $370.2 million in 2025.
  • Its Assets stands at $370.2 million for Q3 2025, versus $334.7 million for Q2 2025 and $315.5 million for Q1 2025.